Order: Signal: Tickers:
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Basic TA News Snapshot Maps Stats
Total: 97 #31
CompanyAthersys, Inc.
Market Cap27.54MEPS (ttm)-8.61
P/E-EPS this Y7.70%
Forward P/E-EPS next Y11.50%
PEG-EPS past 5Y-16.50%
P/S2.57EPS next 5Y-
P/B-EPS Q/Q10.30%
Dividend-Sales Q/Q-
Insider Own0.50%Inst Own13.20%
Insider Trans209.30%Inst Trans-25.49%
Short Float0.21%EarningsAug 11/a
Analyst Recom3.00Target Price3.00
Avg Volume571.64K52W Range2.15 - 41.25
Aug-29-22 06:02PMAthersys shares lose 4.6% on first trading day after reverse stock split American City Business Journals
Aug-25-22 06:43PMAthersys plans reverse stock split by Monday's market opening American City Business Journals
Aug-25-22 04:30PMAthersys Announces 1-for-25 Reverse Stock Split Business Wire
Aug-17-22 04:30PMAthersys, Inc. Announces Closing of $12 Million Registered Direct Offering Business Wire
Aug-15-22 12:16PMAthersys plans to sell $12 million in securities to raise cash for operations American City Business Journals
Aug-15-22 08:30AMAthersys, Inc. Announces $12 Million Registered Direct Offering Business Wire
Aug-14-22 08:13AMNews Flash: One Analyst Just Made An Incredible Upgrade To Their Athersys, Inc. (NASDAQ:ATHX) Forecasts Simply Wall St.
Aug-11-22 10:30PMAthersys (ATHX) Q2 2022 Earnings Call Transcript Motley Fool
Aug-11-22 07:51PMAthersys needs to raise capital to survive, CEO says American City Business Journals
Aug-11-22 04:17PMAthersys Reports Second Quarter 2022 Financial Results and Provides Business Update Business Wire
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Camardo Daniel A.CEOMar 17Buy0.77132,800102,256132,800Mar 17 11:09 AM
Lehmann William JRInterim CEO, President, COODec 15Option Exercise1.285,0006,400481,287Dec 15 11:11 AM
Kola IsmailDirectorNov 19Buy0.9685,00081,702100,000Nov 19 01:34 PM
Macleod ivorChief Financial OfficerNov 17Buy1.1815,00017,706146,583Nov 17 11:16 AM
Lehmann William JRInterim CEO, President, COOOct 28Option Exercise1.285,0006,400476,287Oct 28 10:25 AM
CompanySnap Inc.
IndustryInternet Content & Information
Market Cap19.60BEPS (ttm)-0.51
P/E-EPS this Y51.80%
Forward P/E47.55EPS next Y1406.25%
PEG-EPS past 5Y6.80%
P/S4.32EPS next 5Y-
P/B5.43EPS Q/Q-163.80%
Dividend-Sales Q/Q13.10%
Insider Own8.20%Inst Own62.70%
Insider Trans-1.99%Inst Trans-3.16%
Short Float4.25%EarningsJul 21/a
Analyst Recom2.50Target Price17.21
Avg Volume54.74M52W Range9.34 - 83.34
Sep-08-22 09:04AMBillionaire Stanley Druckenmiller is Selling These 10 Stocks Insider Monkey
Sep-08-22 12:14AMSnap CEO Sees Challenges in Executing Turnaround Drive The Wall Street Journal
Sep-07-22 06:37AMSnap's Problems in 4 Charts Motley Fool
Sep-06-22 05:52PMWhy Apple's digital ad business is gaining an edge over Google and Facebook Yahoo Finance
Sep-06-22 03:09PMSeptember Doesn't Have a Great Track Record When It Comes to Stocks Motley Fool
Sep-06-22 02:12PMWhy Snap Stock Gained 10% in August Motley Fool
Sep-06-22 12:13PMMeta Platforms' (META) Instagram Fined by Irish Regulators Zacks
Sep-05-22 09:15AM3 Top Stocks to Buy in September Motley Fool
Sep-05-22 09:14AM10 Most Important Tech Layoffs to Watch Insider Monkey
Sep-02-22 04:52PMThis week's top movers: Bed Bath & Beyond, Lululemon, Nvidia, Snap Yahoo Finance Video
Snap Inc. operates as a camera company in North America, Europe, and internationally. The company offers Snapchat, a camera application with various functionalities, such as Camera, Communication, Snap Map, Stories, and Spotlight that enable people to communicate visually through short videos and images. It also provides Spectacles, an eyewear product that connects with Snapchat and captures photos and video from a human perspective; and advertising products, including AR ads and Snap ads comprises a single image or video ads, story ads, collection ads, dynamic ads, and commercials. The company was formerly known as Snapchat, Inc. and changed its name to Snap Inc. in September 2016. Snap Inc. was founded in 2010 and is headquartered in Santa Monica, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Thorpe PoppyDirectorAug 17Sale12.2598312,04227,784Aug 19 07:00 PM
O'Sullivan Michael J.General CounselAug 16Sale12.2941,929515,123696,175Aug 18 08:00 PM
Gorman JeremiChief Business OfficerAug 16Sale12.2834,986429,6071,380,160Aug 18 07:00 PM
Andersen DerekChief Financial OfficerAug 16Sale12.2717,206211,1301,070,076Aug 17 07:00 PM
Hunter Jerry JamesSenior VP, EngineeringAug 16Sale12.2861,101750,4851,234,493Aug 16 08:16 PM
CompanyBioAtla, Inc.
Market Cap339.65MEPS (ttm)-2.73
P/E-EPS this Y-147.10%
Forward P/E-EPS next Y3.60%
PEG-EPS past 5Y-
P/S1358.59EPS next 5Y-
P/B1.96EPS Q/Q14.60%
Dividend-Sales Q/Q-
Insider Own5.60%Inst Own67.00%
Insider Trans7.05%Inst Trans-5.56%
Short Float18.32%EarningsAug 09/a
Analyst Recom1.80Target Price29.80
Avg Volume1.08M52W Range2.01 - 39.94
Aug-18-22 06:39AMDo Insiders Own Lots Of Shares In BioAtla, Inc. (NASDAQ:BCAB)? Simply Wall St.
Aug-09-22 07:25PMBioAtla, Inc. (BCAB) Reports Q2 Loss, Lags Revenue Estimates Zacks
Aug-09-22 04:05PMBioAtla Reports Second Quarter 2022 Financial Results And Highlights Recent Progress GlobeNewswire
Aug-03-22 08:00AMBioAtla to Participate in the 2022 BTIG Biotechnology Conference GlobeNewswire
Aug-02-22 08:00AMBioAtla to Announce Second Quarter 2022 Financial Results and Provide Business Highlights on August 9, 2022 GlobeNewswire
Jun-04-22 08:12AMHere's Why We're Watching BioAtla's (NASDAQ:BCAB) Cash Burn Situation Simply Wall St.
Jun-01-22 04:05PMBioAtla to Participate in 2022 Jefferies Global Healthcare Conference GlobeNewswire
May-04-22 04:01PMBioAtla Reports First Quarter 2022 Financial Results and Highlights Recent Progress GlobeNewswire
Apr-08-22 08:00AMBioAtla to Announce First Quarter 2022 Financial Results and Provide Business Highlights on May 4, 2022 GlobeNewswire
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SHORT JAY M PHDChief Executive OfficerAug 12Buy7.8426,350206,6001,396,556Aug 15 04:37 PM
SHORT JAY M PHDChief Executive OfficerJun 22Buy2.9140,308117,2961,375,982Jun 23 04:59 PM
SHORT JAY M PHDChief Executive OfficerJun 21Buy2.7929,08281,0401,335,674Jun 23 04:59 PM
Vasquez ChristianSee RemarksJun 09Buy2.9710,00029,72074,525Jun 09 04:05 PM
Vasquez ChristianSee RemarksJun 08Buy3.0225,84878,18864,525Jun 09 04:05 PM
TickerGME [NYSE]
CompanyGameStop Corp.
IndustrySpecialty Retail
Market Cap7.39BEPS (ttm)-1.56
P/E-EPS this Y-59.10%
Forward P/E-EPS next Y-10.90%
PEG-EPS past 5Y-30.50%
P/S1.21EPS next 5Y-
P/B5.03EPS Q/Q-105.50%
Dividend-Sales Q/Q8.00%
Insider Own15.63%Inst Own27.30%
Insider Trans0.22%Inst Trans-3.02%
Short Float20.72%EarningsSep 07/a
Analyst Recom4.00Target Price13.58
Avg Volume9.35M52W Range19.40 - 63.92
Sep-08-22 10:35AMGameStop announces partnership with crypto exchange FTX Yahoo Finance Video
Sep-08-22 10:15AMThere's No Surrender at GameStop: Trade It Now, Invest Later TheStreet.com
Sep-08-22 09:58AMGameStop CEO was paid $16.8 million in 2021 in total compensation Yahoo Finance Video
Sep-08-22 09:58AMGameStop stock rises after narrower-than expected loss but company remains a mess, Wedbush says MarketWatch
Sep-08-22 09:08AMGameStop's Rising, but This Software Stock Is Thursday's Big Winner Motley Fool
Sep-08-22 08:33AMGameStop Stock Keeps Breaking Its Earnings Season Curse Motley Fool
Sep-08-22 07:55AMGameStop Proves Doubters Wrong. But How Naysayers May Still Be Right. Barrons.com
Sep-08-22 07:44AMAsana, GameStop, Moderna, Revance, and More Stock Market Movers Thursday Barrons.com
Sep-08-22 07:42AMGameStop Posts Mixed Results, Announces Partnership With FTX Bloomberg
Sep-08-22 06:58AMApple Freezes Prices. Its Designed to Keep Consumers Spending. Barrons.com
GameStop Corp., a specialty retailer, provides games and entertainment products through its e-commerce properties and various stores in the United States, Canada, Australia, and Europe. The company sells new and pre-owned gaming platforms; accessories, such as controllers, gaming headsets, virtual reality products, and memory cards; new and pre-owned gaming software; and in-game digital currency, digital downloadable content, and full-game downloads. It also sells collectibles comprising licensed merchandise primarily related to the gaming, television, and movie industries, as well as pop culture themes. As of January 29, 2022, the company operated 4,573 stores and ecommerce sites under the GameStop, EB Games, and Micromania brands; and 50 pop culture themed stores that sell collectibles, apparel, gadgets, electronics, toys, and other retail products under the Zing Pop Culture brand, as well as offers Game Informer, a print and digital video game publication featuring reviews of new releases, previews of the big titles on the horizon, and coverage of the latest developments in the gaming industry. The company was formerly known as GSC Holdings Corp. GameStop Corp. was founded in 1996 and is headquartered in Grapevine, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Attal AlainDirectorMar 24Buy129.911,500194,865130,423Mar 24 07:23 PM
Cohen RyanDirectorMar 22Buy101.76100,00010,176,3429,101,000Mar 22 06:16 PM
Saadeh-Jajeh DianaSVP, Chief Accounting OfficerMar 22Sale125.0074392,87518,825Mar 23 04:41 PM
Cheng LawrenceDirectorMar 21Buy95.844,000383,3558,022Mar 23 04:37 PM
CompanyAgios Pharmaceuticals, Inc.
Market Cap1.58BEPS (ttm)-6.71
P/E-EPS this Y-23.60%
Forward P/E-EPS next Y11.10%
PEG-EPS past 5Y-3.10%
P/S246.80EPS next 5Y39.00%
P/B1.46EPS Q/Q-23.60%
Dividend-Sales Q/Q-
Insider Own0.30%Inst Own-
Insider Trans0.00%Inst Trans-1.68%
Short Float11.42%EarningsAug 04/b
Analyst Recom2.40Target Price34.50
Avg Volume784.14K52W Range16.75 - 50.98
Sep-06-22 08:05AMA Technical Strategy to 'Buy' Agios Pharmaceuticals TheStreet.com
Sep-02-22 04:02PMAgios Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating Investor's Business Daily
Aug-24-22 07:00AMAgios to Participate in September Investor Conferences GlobeNewswire
Aug-18-22 06:35PMAgios Announces Publication of Phase 3 ACTIVATE-T Data in The Lancet Haematology Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency GlobeNewswire
Aug-15-22 08:00AMAgios Appoints Rahul Ballal and Cynthia Smith to Board of Directors GlobeNewswire
Aug-11-22 06:35PMAgios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent - and -Thalassemia GlobeNewswire
Aug-11-22 10:01AMProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox GlobeNewswire
Aug-08-22 06:36PMAgios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Executive Officer GlobeNewswire
Aug-08-22 08:41AMEven after rising 38% this past week, Agios Pharmaceuticals (NASDAQ:AGIO) shareholders are still down 49% over the past five years Simply Wall St.
Aug-05-22 12:20PMAgios (AGIO) Q2 Loss Narrower Than Expected, Sales Beat Zacks
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ho MaykinDirectorMay 20Option Exercise0.001,58506,549May 24 04:11 PM
MARAGANORE JOHNDirectorMay 20Option Exercise0.001,585030,028May 24 04:10 PM
Foster-Cheek Kaye IDirectorMay 20Option Exercise0.001,58508,749May 24 04:10 PM
CLARK IAN TDirectorMay 20Option Exercise0.001,58506,549May 24 04:12 PM
Schenkein David PDirectorMay 20Option Exercise0.001,5850117,879May 24 04:11 PM
CompanyPROCEPT BioRobotics Corporation
IndustryMedical Devices
Market Cap2.00BEPS (ttm)-1.56
P/E-EPS this Y-9.30%
Forward P/E-EPS next Y22.00%
PEG-EPS past 5Y-
P/S40.27EPS next 5Y52.70%
P/B8.31EPS Q/Q33.20%
Dividend-Sales Q/Q6.40%
Insider Own3.30%Inst Own80.70%
Insider Trans-46.30%Inst Trans9.92%
Short Float5.80%EarningsAug 04/a
Analyst Recom2.00Target Price47.71
Avg Volume449.63K52W Range15.38 - 47.73
Aug-22-22 04:03PMPROCEPT BioRobotics Corp. to Present at 2022 Wells Fargo Healthcare Conference GlobeNewswire
Aug-05-22 05:30PMPROCEPT BioRobotics Corporation (PRCT) Q2 2022 Earnings Call Transcript Motley Fool
Aug-04-22 04:03PMPROCEPT BioRobotics Reports Second Quarter 2022 Financial Results and Increases 2022 Revenue Guidance GlobeNewswire
Jul-14-22 04:02PMPROCEPT BioRobotics to Report Second Quarter 2022 Financial Results on August 4, 2022 GlobeNewswire
Jul-10-22 08:32AMInsiders of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) received good value on their investment after their US$11m purchase jumped US$3.3m in value Simply Wall St.
Jun-16-22 02:30PMProcept Biorobotics Corp Joins Elite Club Of Stocks With RS Ratings Over 90 Investor's Business Daily
Jun-09-22 09:01AMHow Much Of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Do Insiders Own? Simply Wall St.
Jun-09-22 08:00AMPROCEPT BioRobotics Corporation Announces Additional Positive Coverage Policies Regarding Aquablation Therapy for Men with Enlarged Prostates GlobeNewswire
May-10-22 06:20AMNeed To Know: Analysts Are Much More Bullish On PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Revenues Simply Wall St.
May-05-22 04:02PMPROCEPT BioRobotics Reports First Quarter 2022 Financial Results and Increases 2022 Revenue Guidance GlobeNewswire
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Krummel Thomas MDirectorJun 22Option Exercise4.512,68912,134102,920Jun 22 07:11 PM
Krummel Thomas MDirectorJun 21Option Exercise2.5917,31144,773100,231Jun 22 07:11 PM
Krummel Thomas MDirectorJun 21Sale35.9820,000719,65382,920Jun 22 07:11 PM
Nouri AlalehEVP, CLO, CORP. SEC.May 16Sale35.0667823,77146,468May 16 05:49 PM
VIKING GLOBAL INVESTORS LP10% OwnerMar 18Sale29.901,249,00037,345,100298,205Mar 22 08:51 PM
CompanyStarbox Group Holdings Ltd.
IndustryInternet Content & Information
Market Cap153.00MEPS (ttm)0.06
P/E56.67EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S25.63EPS next 5Y-
P/B53.97EPS Q/Q-
Dividend-Sales Q/Q2352.90%
Insider Own64.44%Inst Own-
Insider Trans-Inst Trans-
Short Float-Earnings-
Analyst Recom-Target Price-
Avg Volume8.23M52W Range3.39 - 46.21
Aug-25-22 01:00PMStarbox Group Holdings Ltd. Announces Closing of US$21.5 million Initial Public Offering Including Partial Exercise of Over-Allotment Option GlobeNewswire
Aug-22-22 08:00PMStarbox Group Holdings Ltd. Announces Pricing of US$20 million Initial Public Offering GlobeNewswire
Starbox Group Holdings Ltd., through its subsidiaries, provides digital advertising services to retail merchant advertisers through websites and mobile apps in Malaysia. It connects retail merchants with individual online and offline shoppers to facilitate transactions through cash rebate programs offered by retail merchants. The company also provides payment solutions to merchants; and network marketing services. Starbox Group Holdings Ltd was founded in 2019 and is based in Kuala Lumpur, Malaysia.
TickerINM [NASD]
CompanyInMed Pharmaceuticals Inc.
Market Cap124.54MEPS (ttm)-1.37
P/E-EPS this Y34.20%
Forward P/E-EPS next Y51.00%
PEG-EPS past 5Y-
P/S216.71EPS next 5Y-
P/B5.97EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own0.78%Inst Own9.05%
Insider Trans25.83%Inst Trans-
Short Float-Earnings-
Analyst Recom3.00Target Price3.40
Avg Volume35.45K52W Range5.82 - 59.25
Aug-23-22 05:00PMInMed Announces Share Consolidation to Meet Nasdaq Listing Criteria GlobeNewswire
Aug-09-22 07:30AMInMed Announces Changes to its Board of Directors GlobeNewswire
Jul-25-22 07:30AMInMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa GlobeNewswire
Jul-18-22 07:30AMInMed Announces Appointment of Chief Operating Officer GlobeNewswire
Jul-12-22 11:33PMInMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance GlobeNewswire
Jun-14-22 07:30AMInMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions GlobeNewswire
Jun-09-22 07:30AMInMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector GlobeNewswire
Jun-06-22 06:49PMInMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules GlobeNewswire
Jun-02-22 08:00AMInMed Pharmaceuticals Announces $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules GlobeNewswire
May-13-22 08:45AMInMed Pharmaceuticals Inc. (INM) Reports Q3 Loss, Misses Revenue Estimates Zacks
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ADAMS ERIC APresident & CEOApr 14Buy0.8914,16012,65959,003Apr 18 11:46 AM
ADAMS ERIC APresident & CEOApr 13Buy0.858,5607,27644,843Apr 13 09:43 PM
COLWILL BRUCECFOJan 24Buy1.095,0005,43811,515Jan 24 02:02 PM
Johnson Shane AaronSVP, GM of BayMedica LLCJan 06Buy1.268,50010,710304,595Jan 06 06:40 PM
Johnson Shane AaronSVP, GM of BayMedica LLCDec 30Buy1.338,09310,736296,095Dec 30 07:22 PM
CompanyAeroClean Technologies, Inc.
IndustryPollution & Treatment Controls
Market Cap52.07MEPS (ttm)-0.89
P/E-EPS this Y-153.80%
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S74.38EPS next 5Y-
P/B2.77EPS Q/Q-44.00%
Dividend-Sales Q/Q-
Insider Own62.48%Inst Own12.10%
Insider Trans0.00%Inst Trans-
Short Float9.22%Earnings-
Analyst Recom2.00Target Price7.00
Avg Volume7.96M52W Range1.76 - 117.35
Aug-16-22 07:00AMAeroClean Reports Second Quarter 2022 Financial Results GlobeNewswire
Aug-10-22 10:00AMAeroClean Technologies Proven to Eliminate the Active Omicron Variant of SARS-CoV-2 in the Air GlobeNewswire
Jul-27-22 08:00AMAeroClean Deploys Safe Air Technology at Notable Hospitality & Club Spaces through Partnership with the Florida Chapter of the Club Management Association of America (FLCMAA) GlobeNewswire
Jul-04-22 02:39PMHow Much Of AeroClean Technologies, Inc. (NASDAQ:AERC) Do Insiders Own? Simply Wall St.
Jun-29-22 02:19PMAeroClean Technologies, Inc. Announces Closing of $15.0 Million Private Placement GlobeNewswire
Jun-27-22 09:00AMAeroClean Technologies, Inc. Announces $15.0 Million Private Placement GlobeNewswire
Jun-22-22 08:00AMTraders News Source Editor, Mark Roberts Interviews Jason DiBona CEO AeroClean Technologies, Inc. ACCESSWIRE
Jun-14-22 03:57PMBenchmark Downgrades AeroClean After Share Price Rallies Benzinga
Jun-08-22 08:00AMAeroClean Announces Appointment of Jimmy Thompson as Vice President of Strategic Sales GlobeNewswire
Jun-06-22 09:49AMAeroClean Receives FDA Clearance For Prgo Medical Grade Air Hygiene Technology GlobeNewswire
AeroClean Technologies, Inc., an interior space air purification technology company, provides air purification solutions for hospitals and other healthcare facilities. It offers interior air sterilization and disinfection products for the eradication of harmful airborne pathogens, including COVID-19. It provides Purgo, an air filtration machine; and Purgo Lift, an air purification solution for elevators and other wall-mount applications. The company was formerly known as AeroClean Technologies, LLC. AeroClean Technologies, Inc. was founded in 2011 and is headquartered in Palm Beach Gardens, Florida.
CompanyMaxeon Solar Technologies, Ltd.
Market Cap955.32MEPS (ttm)-7.04
P/E-EPS this Y-16.70%
Forward P/E-EPS next Y73.60%
PEG-EPS past 5Y-
P/S1.06EPS next 5Y-
P/B5.32EPS Q/Q-8.00%
Dividend-Sales Q/Q35.40%
Insider Own49.76%Inst Own39.50%
Insider Trans0.00%Inst Trans3.46%
Short Float11.81%EarningsAug 18/a
Analyst Recom2.60Target Price20.20
Avg Volume525.92K52W Range7.48 - 25.39
Sep-08-22Upgrade Goldman Sell → Buy $9 → $27
Sep-08-22 09:00AMMaxeon Solar Technologies Announces Leadership Changes; Jeff Waters to Step Down and CRO Mark Babcock Appointed Interim CEO, Effective September 15, 2022 PR Newswire
Aug-18-22 04:05PMMaxeon Solar Technologies Announces Second Quarter 2022 Financial Results PR Newswire
Aug-12-22 09:05AMMaxeon Solar Technologies to Release Second Quarter 2022 Financial Results on August 18, 2022 PR Newswire
Aug-03-22 01:43PMHow Much Of Maxeon Solar Technologies, Ltd. (NASDAQ:MAXN) Do Institutions Own? Simply Wall St.
Aug-02-22 08:05AMSunPower Reports Second Quarter 2022 Results PR Newswire
Jul-29-22 08:55AMMaxeon Solar Technologies Supports Inflation Reduction Act, Urges Swift Passage Through Congress PR Newswire
Jul-04-22 01:34PMAn Intrinsic Calculation For Maxeon Solar Technologies, Ltd. (NASDAQ:MAXN) Suggests It's 47% Undervalued Simply Wall St.
Jun-30-22 08:57AMMaxeon Solar Technologies Releases 2021 Sustainability Report with Energy Payback Time, Long Term Targets PR Newswire
Jun-30-22 08:52AMSunPower Stock Sinks as Analyst Sees U.S. Solar Policy as Stiff Headwind Barrons.com
Jun-06-22 04:05PMMaxeon Solar Technologies Announces the Appointment of a New Independent Director PR Newswire
Maxeon Solar Technologies, Ltd. designs, manufactures, markets, and sells solar panels and related solar system components worldwide. The company provides interdigitated back contact and shingled solar cells and panels under the SunPower brand. It offers its products to dealers, project developers, system integrators, distributors, resellers, and residential and small-scale commercial customers. Maxeon Solar Technologies, Ltd. was incorporated in 2019 and is headquartered in Singapore.